Cancer is a product of cellular changes that cause disease through the uncontrolled growth and division of cells. Over the past 150 years, many hypotheses have been proposed to explain the origin of cancer cells. These include the unregulated proliferation of cancer cells, metastasis and the histological classification of the cancer tissue (benign or malignant tumour).
In 1845, Rudolf Virchow found abnormal increases in white blood cells in some patients, and in 1847 identified the condition as a blood disease called leukämie (leukaemia). In 1857, Virchow was the first to identify chordoma, a tumour developed at the skull’s base. Also, in 1858, he presented that cancer cells are the body’s own cells.
Currently, the most accepted theory of cancer is based on the hysteron proteron of the somatic mutation theory (SMT). In this model, the first event (mutations) occurs after the cell has been transformed from a normal cell to a cancer cell via a process termed carcinogenesis. These mutations have increasingly been perceived as the causal event in the origin of the vast majority of cancers.
Currently, this model is challenged by a growing amount of experimental data and arguments that could either not be explained by the model or contradict this model.
One study of three subtypes of ependymoma (glioma) brain tumours found that one subtype carried an intrachromosomal translocation (a segment breaking off the chromosome and rejoining it at a different location), creating a new tumour-driving gene. The second subtype lacked tumour-driving mutations and had epigenetic modifications compared to the third subtype, which had neither gene mutations nor epigenetic aberrations.
Furthermore, the fact that normal tissues can display massive genetic changes, including changes in cancer-initiating and cancer-driving genes. Over the past few decades, several transfer experiments have demonstrated tumour-suppressing effects on normal cytoplasm. These include mitochondrial transfer, which has the ability to suppress tumour growth. This could be demonstrated – despite the presence of cancerous nuclear genomes – by showing the introduction of non-cancerous mitochondria into highly malignant breast cancer cells. This approach reversed the malignancy and down-regulated several oncogenic pathways, such as invasion and in vivo tumour growth.
Moreover, several non-genotoxic (non-mutagenic) carcinogens, including dichlorobenzene and chloroform, initiate cancer formation. Other oncological theories include oxidative phosphorylation, which results in cellular energy loss and highly impacts cancer formation.
Currently, several imaging modalities are available to clinicians who diagnose, stage and treat human cancer: X-ray (plain film and computed tomography), ultrasound, magnetic resonance imaging, single-photon emission computed tomography, positron emission tomography and optical imaging. Of these, only four (MRI, CT, PET and SPECT) are capable of 3-D detection of cancer anywhere in the human body.
You are here:
home »
By
| 5 minutes of readingDiscover how experimental treatments legal disputes arise when cutting-edge therapies meet traditional malpractice law challenges.
When Experimental Treatments Become Legal Disputes Read Article »
By
| 8 minutes of readingRelative dosimetry in radiation therapy enables precise measurement of dose distribution for effective and safe treatment delivery.
The Science and Precision of Relative Dosimetry in Radiation Therapy Read Article »
By
| 7 minutes of readingElectron Beam Treatment Planning delivers precise, shallow-dose radiation, ideal for targeting superficial tumours while sparing deeper tissues.
Precision at the Surface: Cutting-Edge Techniques in Electron Beam Treatment Planning Read Article »
By
| 6 minutes of readingLearn about Chronic Lymphocytic Leukemia, a common cancer in adults, and how it affects the body and health over time.
Chronic Lymphocytic Leukemia: Advancing Therapies and Living with Hope Read Article »
By
| 12 minutes of readingPancreas plays a central role in digestion and metabolism by producing essential enzymes and hormones for bodily regulation.
How the Pancreas Works: Functions and the Role of Medical Imaging Read Article »
By
| 7 minutes of readingBest Dermatologist in Austin, TX provides comprehensive skin care, specialising in acne treatment, cosmetic procedures, and skin cancer screenings.
Finding the Best Dermatologist in Austin, TX Read Article »
By
| 7 minutes of readingRadiation therapy support significantly improves patient well-being, addressing physical symptoms, emotional needs, and enhancing treatment outcomes. Image for illustration only. Person depicted is a model.
How Can You Best Support Patients Undergoing Radiation Therapy? Read Article »
By
| 11 minutes of readingRobotic-assisted biopsy significantly enhances precision, enabling earlier lung cancer diagnosis and improving patient treatment outcomes effectively.
Transforming Early Lung Cancer Detection: The Power of Robotic-Assisted Biopsy Read Article »
By
| 10 minutes of readingYttrium-90 Tabituximab barzuxetan is a radiolabelled drug designed for targeted synovial sarcoma treatment.
By
| 10 minutes of readingYttrium-90 FAPi-46 targets fibroblast activation protein, providing effective radiotherapy for tumours and fibrotic diseases.
By
| 9 minutes of readingYttrium-90 FAPi-04 is a promising radiotherapeutic targeting fibroblast activation protein in cancer-associated fibroblasts effectively.
Yttrium-90 FAPi-04: A Novel Radiotherapeutic Targeting Fibroblast Activation Protein Read Article »
By
| 11 minutes of readingYttrium-90 Basiliximab combines targeted immunotherapy and radiotherapy, selectively attacking CD25-positive tumours with high therapeutic precision.
By
| 11 minutes of readingYttrium-90 Anditixafortide targets CXCR4-expressing tumours, delivering therapeutic β– radiation precisely, improving treatment outcomes significantly.
By
| 5 minutes of readingRhenium-SCT®: Innovative, precise, non-surgical therapy for non-melanoma skin cancer, ensuring safe and effective outcomes.
The Rhenium-SCT®: A Breakthrough in Non-Melanoma Skin Cancer Treatment Read Article »
By
| 8 minutes of readingRADIOPHARMACEUTICAL INNOVATION merges cutting-edge radiochemistry, targeted biology, and global clinical expertise, enhancing personalised treatments in oncology.
Radiopharmaceutical Innovation: An Overview for Targeted Therapy Read Article »
By
| 14 minutes of readingRhenium-188 HDD/Lipiodol therapy offers targeted radiopharmaceutical treatment for advanced hepatocellular carcinoma with portal vein thrombosis.
By
| 13 minutes of readingRhenium-188 P2045 is a peptide-based radiopharmaceutical targeting somatostatin receptors for treating neuroendocrine and pancreatic cancers.
By
| 12 minutes of readingLead-203 DOTA-VMT-MCR1 binds MC1R with high specificity, facilitating targeted imaging and image-guided therapy for metastatic melanoma patients.
By
| 15 minutes of readingNutraceuticals for health combine nature and science to enhance immunity, support digestion, and promote long-term wellness.
Nutraceuticals: Bridging the Gap Between Nutrition and Pharmaceuticals Read Article »
By
| 11 minutes of readingLutetium-177 MVT-1075 radioimmunotherapy targets pancreatic cancer by utilising CA19-9 specificity, sialyl-Lewis a binding, and precision radiation delivery.
Lutetium-177 MVT-1075: A Breakthrough in Pancreatic Cancer Radioimmunotherapy Read Article »
By
| 12 minutes of readingAdvanced dermatological imaging provides detailed insights into skin layers, enhancing early disease detection, treatment accuracy, and overall patient care significantly.
Unveiling Skin’s Secrets: The Power of Medical Imaging Read Article »
By
| 11 minutes of readingLung function involves oxygen exchange, carbon dioxide removal, and maintaining optimal respiratory efficiency for overall bodily health. Image for illustration only. Person depicted is a model.
By
| 6 minutes of readingGenomic research revolutionises healthcare by providing insights into diseases, enabling precise treatments, and improving patient outcomes worldwide.
By
| 4 minutes of readingA novel radiolabelled drug, Lutetium-177 LNC1004, targets fibroblast activation protein, transforming cancer therapy through precision and innovation.
By
| 5 minutes of readingBetalutin combines the precision of CD37-targeting antibody Lilotomab with Lutetium-177, offering targeted and effective haematological cancer treatment.
Betalutin: A Revolutionary Therapeutic Pathway in Haematological Cancer Treatment Read Article »
By
| 5 minutes of readingTargeting Neurotensin Receptor-1 with Lutetium-177 IPN-01087 demonstrates promising precision therapy, delivering beta radiation for treating invasive cancers like ductal pancreatic adenocarcinoma.
Targeting Neurotensin Receptor-1: Lutetium-177 IPN-01087 in Oncology Read Article »
By
| 4 minutes of readingRevolutionising cancer therapy, Lutetium-177 FAP-2286 offers precise diagnostics and targeted treatment, addressing solid tumours and fibrotic conditions effectively.
By
| 6 minutes of readingmRNA technology revolutionises medicine by enabling rapid, cost-effective treatments, including vaccines, cancer therapies, and solutions for genetic and chronic diseases.
mRNA Technology: A Revolution in Medical Science Read Article »
By
| 5 minutes of readingAI algorithms revolutionise tumour detection in medical imaging, enhancing precision, automating analysis, and supporting personalised cancer treatment through advanced PET/CT integration.
AI Algorithms Transforming Tumour Detection in Medical Imaging Read Article »
By
| 5 minutes of readingLutetium-177 Debio 1124, a second-generation theranostic agent, selectively targets CCK2R-expressing tumours, offering precision radiotherapy and personalised oncology advancements.
By
| 4 minutes of readingThe rise and fall of Iodine-131 Tositumomab highlights challenges in balancing innovation, efficacy, infrastructure, and cost within radiopharmaceutical therapies.
The Rise and Fall of Iodine-131 Tositumomab: Bexxar’s Story Read Article »
